Aim: The aim of this study is to investigate the maternal levels of collectrin in early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE). To assess the correlation between serum collectrin levels and blood pressure in humans.

Material And Methods: This cross-sectional study was conducted including 79 pregnant women, 27 with normal pregnancy, 30 with EOPE and 22 with LOPE. Maternal serum levels of collectrin were measured by using enzyme-linked immunosorbent assay kits.

Results: The mean serum collectrin level was significantly lower in women with PE compared with the control group (8.49 ± 3.12 ng/ml (EOPE), 9.69 ± 3.01 ng/ml (LOPE) versus 11.51 ± 4.33 ng/ml) and was found to be the lowest in the EOPE group (8.49 ± 3.12 ng/ml). The mean serum urea and uric acid levels were significantly higher in the PE group than the control group. Serum collectrin concentrations did not correlate with maternal age, BMI and serum creatinine levels. However, collectrin concentrations were negatively correlated with systolic blood pressure (r = -0.284, p = .011) and diastolic blood pressure (r = -0.275, p = .014) as well as with maternal serum urea (r = -0.269, p = .017) and uric acid (r = -0.219, p = .049) concentrations.

Conclusion: Maternal serum collectrin levels are significantly lower in patients with preeclampsia than in the control group. There is an inverse correlation between serum collectrin levels and blood pressure.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2017.1357692DOI Listing

Publication Analysis

Top Keywords

serum collectrin
24
collectrin levels
16
blood pressure
16
levels collectrin
12
maternal serum
12
control group
12
serum
10
levels
8
late-onset preeclampsia
8
collectrin
8

Similar Publications

Article Synopsis
  • As SARS-CoV-2 evolves, it becomes resistant to therapeutic antibodies but maintains its ability to bind to the ACE2 receptor needed for infection.
  • Researchers developed an ACE2 decoy that effectively neutralizes antibody-resistant variants, including Omicron, without losing effectiveness.
  • The study reveals that adding the ACE2 collectrin-like domain improves the decoy's performance by enhancing binding, extending its lifespan in the bloodstream, and reducing disease severity in animal models.
View Article and Find Full Text PDF

Urinary Collectrin (TMEM27) as Novel Marker for Acute Kidney Injury.

Life (Basel)

September 2022

Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, 1090 Vienna, Austria.

Acute kidney injury (AKI) is a leading complication in hospitalized patients of different disciplines due to various aetiologies and is associated with the risk of chronic kidney disease, the need for dialysis and death. Since nephrons are not supplied with pain signals, kidney injury is mostly diagnosed by serum creatinine with a time delay. Recent work has shown that certain urinary biomarkers are available for early detection of AKI.

View Article and Find Full Text PDF

Background: Pre-eclampsia is a major contributor to pregnancy-associated morbidity and mortality and the management of this complex syndrome needs to be improved. Recently serum collectrin has emerged as a new member of the renin-angiotensin system that regulates the blood pressure through nitric oxide -endothelial nitric oxide synthase pathway.

Objective: To evaluate the correlation of serum collectrin level and preeclampsia onset.

View Article and Find Full Text PDF

Aim: The aim of this study is to investigate the maternal levels of collectrin in early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE). To assess the correlation between serum collectrin levels and blood pressure in humans.

Material And Methods: This cross-sectional study was conducted including 79 pregnant women, 27 with normal pregnancy, 30 with EOPE and 22 with LOPE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!